硼替佐米治疗多发性骨髓瘤的临床观察及检验指标-第三军医大学学报.docVIP

硼替佐米联合化疗对多发性骨髓瘤的疗效与相关血液学指标分析 杨再林张勇夏顺中秦大兵白海雁田小波陈润徐双年陈洁平 （第三军医大学西南医院血液病中心，重庆400038重庆医科大学医学检验系临床检验诊断学教育部重点实验室，重庆400016；) 观察硼替佐米治疗多发性骨髓瘤（MM）的疗效指标的改变。 2007年4月至2009年3月院血液病中心收治的8例多发性骨髓瘤患者。其中2例初治患者与6例复发难治患者，均采用硼替佐米联合化疗，3周为1疗程。观察疗效及相关指标的。 2例初发患者中1例患者完全缓解（CR）后行自体造血干细胞移植，1例患者获得部分缓解（PR）。6例复发难治患者中1例达PR，4例达CR，1例无效。患者浆细胞比例、血清总蛋白含量（TP）、球蛋白（G）、M蛋白含量，尿蛋白、β2-微球蛋白乳酸脱氢酶（LDH）等随化疗周期呈明显下降趋势，患者血红蛋白（Hb）、白蛋白(ALP)含量、A/G比值等呈明显的上升趋势。 硼替佐米对初发及难治复发多发性骨髓瘤的治疗均有较好疗效，治疗副反应患者可耐受，相关指标改善明显。 多发性骨髓瘤；硼替佐米；疗效；不良反应；指标图分类号： 【作者简介】杨再林（023）687,军线7731142001747@163.com 通作者：陈洁平 电话（023E-mail: chenjpxn@ Bortezomib combined with chemotherapy on multiple myeloma and related hematological changes analysis YANG Zai-Lin1，ZHANG Yong1，ZHANG Ling2，XIA Shun-Zhong1，PEI Li1，QIN Da-Bing1，BAI Hai-Yan1，TIAN Xiao-Bo1，ZHU Yan1，CHEN Run1，XU Shuang-Nian1，CHEN Jie-Pin1 (1Centrer of hematolog，Southwest Hospital，Third Military Medical University，Chongqing 400038,2Faculty of Laboratory Medicine, Chongqing Medical University (CQMU), Key Laboratory cf Laboratory Medical Diagnostics of Ministry Of Education, Chongqing 400016,China) Abstract Objective To observe the bortezomib treatment of multiple myeloma (MM) of the efficacy and hematological changes. Methods from april 2007 to march 2009 third military medical university the first affiliated hospital of hematology department, admitted to eight cases of patients with multiple myeloma. These two cases of newly diagnosed patients and six cases with relapsed or refractory patients, all with bortezomib combined with chemotherapy, 3 weeks for a course of treatment. Evaluate the efficacy and related hematological changes. Results The results of two cases of newly diagnosed patients, 1 patients with complete remission (CR) Across autologous hematopoietic stem cell transplantation, 1 patient obtained partial remission (PR). 6 cases of refractory and relapsed patients, 1 case up to PR, 4 case reached CR, 1 patients were NR. The proportion of plasma cells in patients with serum tota